2026-05-14T14:30:27-05:00 2025-12-31 233018514 DUNLAPSLK PC 1300 HORIZON DRIVE SUITE 106 CHALFONT PA 18914 990 2025-01-01 232740843 ALTERNATIVES RESEARCH AND DEVELOPMENT FOUNDATION ALTE 2158878076 801 OLD YORK ROAD 218 JENKINTOWN PA 19046 LUKE KLEIN PRESIDENT 2158878076 2026-05-11 1 JULIA L DAVIS P00163568 2675943755 2026-05-08 2025 2025-03-06 01:10:19Z LUKE KLEIN 801 OLD YORK ROAD 218 JENKINTOWN PA 19046 3841334 0 X WWW.ARDF-ONLINE.ORG X 1993 PA ARDF PROMOTES AND DEVELOPS ALTERNATIVE SCIENTIFIC SOLUTIONS TO THE PROBLEM OF ANIMAL TESTING. 8 6 2 10 0 0 1233029 79690 0 0 896388 1311971 0 0 2129417 1391661 413605 432731 0 0 54703 61082 0 0 7429 366181 453596 834489 947409 1294928 444252 16848676 17124006 44137 105402 16804539 17018604 X THE MISSION OF THE ARDF IS TO FUND AND PROMOTE THE DEVELOPMENT, VALIDATION AND ADOPTION OF NON-ANIMAL METHODS IN BIOMEDICAL RESEARCH, PRODUCT TESTING, AND EDUCATION. 0 0 751037 432731 THE "ANNUAL OPEN" GRANT PROGRAM FUNDS INNOVATIVE NON-ANIMAL METHODS TO REDUCE OR REPLACE ANIMAL USE IN RESEARCH AND TESTINGIN 2025, ARDF FUNDED THE FOLLOWING PROJECTS FOR SCIENTIFIC RESEARCH: 1) ENGINEERED HUMAN HEART MODELS FOR ADVANCING DRUG CARDIAC SAFETY ASSESSMENT; 2) IN VITRO MODELLING OF BUBBLE-ASSISTED FOCUSED ULTRASOUND BLOOD-BRAIN BARRIER OPENING; 3) AN ADVANCED EX VIVO MODEL FOR IDIOPATHIC PULMONARY FIBROSIS; 4) REPLACING ANIMAL-DERIVED PRODUCTS IN DRUG DEVELOPMENT IN VITRO MODELS; 5) IMMUNE DISRUPTORS AND THE DEVELOPING BRAIN: UNRAVELING HOW IMMUNOTOXICANTS SHAPE NEURODEVELOPMENT; 6) ADVANCING ORGANOID INTELLIGENCE WITH A HIPPOCAMPAL-CORTICAL SYSTEM; 7) GENERATION OF THE OLFACTORY EPITHELIUM FROM HUMAN PLURIPOTENT STEM CELLS TO STUDY NEURODEGENERATION; AND 8) A HUMAN-RELEVANT MODEL FOR REAL-TIME MONITORING OF MYCN-DRIVEN NEUROBLASTOMA SPREADING AND DRUG TESTING. THESE PROJECTS REFLECT ARDF'S CONTINUED EMPHASIS ON SUPPORTING HUMAN-RELEVANT, ANIMAL-FREE APPROACHES FOR BIOMEDICAL RESEARCH AND DRUG DEVELOPMENT, INCLUDING CELL- AND TISSUE-BASED SYSTEMS, ORGANOID AND STEM CELL TECHNOLOGIES, COMPUTATIONALLY INFORMED MODELS, AND OTHER ADVANCED IN VITRO AND EX VIVO METHODS. BY SUPPORTING RESEARCH TO DEVELOP AND ADVANCE ALTERNATIVE, ANIMAL-FREE MODELS, ARDF CONTINUES TO PROMOTE BOTH ANIMAL WELFARE AND HUMAN HEALTH. ARDF ALSO CONTINUED DEVELOPMENT OF ITS ALTERNATIVES IN RESEARCH CHALLENGE, A DISEASE-FOCUSED GRANT INITIATIVE SUPPORTING NON-ANIMAL APPROACHES TO CHILDHOOD CANCER RESEARCH. ARDF ALSO CONTRIBUTES ITS EXPERTISE TO SCIENTIFIC AND POLICY DISCUSSIONS CONCERNING THE ADVANCEMENT, VALIDATION, AND ADOPTION OF NON-ANIMAL METHODS. IN 2025, ARDF SUPPORTED EDUCATION, OUTREACH, AND SCIENTIFIC EXCHANGE TO ACCELERATE UNDERSTANDING OF HUMAN-RELEVANT APPROACHES AND TO FOSTER COLLABORATION AMONG RESEARCHERS, POLICYMAKERS, AND OTHER STAKEHOLDERS. 751037 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 X 2 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 PA MN X X THE ORGANIZATION 2158878076 801 OLD YORK ROAD SUITE 218 JENKINTOWN PA 19046 SUE LEARY PRESIDENT (PRIOR TO 10/7/25) 12.00 35.00 X X 15462 41090 2239 LUKE KLEIN PRESIDENT (AFTER 10/7/25) 12.00 35.00 X X 4538 105685 15793 NADIA S ADAWI BOARD MEMBER 0.50 0.50 X 0 0 0 ROBERT FINN BOARD MEMBER 0.50 0.50 X 0 0 0 EILEEN SMITH BOARD MEMBER 0.50 0.50 X 0 0 0 JOSEPH LUDWIG VICE PRESIDENT 0.50 1.00 X X 0 0 0 AARON MCINTYRE TREASURER 0.50 1.00 X X 0 0 0 DENISE COWIE SECRETARY 0.50 1.00 X X 0 0 0 20000 146775 18032 1 0 0 0 MORGAN STANLEY 1585 BROADWAY NEW YORK NY 10036 INVESTMENT SERVICES 147723 1 79690 79690 285586 285586 3476058 2449673 1026385 1026385 1026385 1391661 0 0 1311971 X 332731 332731 100000 100000 20000 20000 28305 9621 13211 5473 9901 4639 3883 1379 2876 1324 1101 451 108 108 18735 18735 147723 147723 215641 215195 393 53 12241 9137 3031 73 19548 18890 658 33957 33957 600 600 79 59 20 RESEARCH AND INFORMATIO 4739 4706 33 POSTAGE AND SHIPPING 225 178 47 947409 751037 188943 7429 46218 25065 2260339 2298163 18069 18069 3250 3250 12396 12096 900 300 14050290 14287793 469610 491366 16848676 17124006 3677 5642 40460 99760 44137 105402 X 14624283 14738597 2180256 2280007 16804539 17018604 16848676 17124006 X 444252 -267041 36854 X X 0 1 X 1 0 X 69409 333654 77619 1233029 79690 1793401 69409 333654 77619 1233029 79690 1793401 1793401 154090 140054 185725 241189 285586 1006644 8505 8505 2808550 0.63860 0.67230 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 13896 260 11044 260 24940 750777 3501971 751037 3526911 137656 326346 34414 81587 0 0 0 0 293887 330620 0 137656 762163 1143245 22629 21761 0 260 44650 73472 82655 0 34414 190541 285812 15679 15342 0 31021 14050290 857503 620000 14287793 12634377 1975913 560000 14050290 10366590 2667787 400000 12634377 14214680 -3448036 400054 10366590 12674289 1890391 350000 14214680 1.00000 0.00000 0.00000 0 0 12396 12096 300 300 LEASE OBLIGATIONS 25160 PAYABLE TO AFFILIATE 74600 99760 X 1013751 -267041 36854 -230187 1243938 147723 147723 1391661 799686 0 799686 147723 147723 947409 PART V, LINE 4: THE ORGANIZATION'S QUASI-ENDOWMENT FUNDS FUND THE VARIOUS ACTIVITIES OF ARDF. THIS INCLUDES FUNDING RESEARCH PROJECTS THAT DEVELOP NON-ANIMAL ALTERNATIVES TO TRADITIONAL ANIMAL EXPERIMENTS AND SPONSORSHIP OF SCIENTIFIC MEETINGS PROMOTING ALTERNATIVES. PART X, LINE 2: MANAGEMENT BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX PROVISIONS TAKEN, AND AS SUCH, THE FOUNDATION DOES NOT HAVE ANY UNCERTIAN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: UNREALIZED GAIN ON BENEFICIAL INTEREST IN PERPETUAL TRUST 36,854. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 2 PROGRAM SERVICES GRANT PROGRAM MANAGEMENT 202420 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES RESEARCH GRANTS 100000 0 2 0 0 0 2 302420 0 302420 SPAIN DR. ARANZAZU VILLASANTE RESEARCH GRANT A HUMAN-RELEVANT MODEL FOR REAL-TIME MONITORING OF MYCN-DRIVEN NEUROBLASTOMA SPREADING AND DRUG TESTING 50000 WIRE TRANSFER 0 SWEDEN DR. MARIA KARLGREN RESEARCH GRANT REPLACING ANIMAL-DERIVED PRODUCTS IN DRUG DEVELOPMENT IN VITRO MODELS 50000 WIRE TRANSFER 0 0 0 0 0 0 0 PART I, LINE 2: PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND THE FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY. 1 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI OH 45229 310833936 501(C)(3) 50000 0 DR. JASON TCHIEU RESEARCH GRANT GENERATION OF THE OLFACTORY EPITHELIUM FROM HUMAN PLURIPOTENT STEM CELLS TO STUDY NEURODEGENERATION INSTITUTE FOR IN VITRO SCIENCES INC 30 W WATKINS MILL ROAD SUITE 100 GAITHERSBURG MD 20878 522029668 501(C)(3) 27500 0 SUPPORT OF IIVS EDUCATION AND OUTREACH PROGRAM JOHNS HOPKINS UNIVERSITY JUHRA 1101 E 33RD ST BALTIMORE MD 21218 520595110 501(C)(3) 99555 0 DR. FENNA SILLE RESEARCH GRANT IMMUNE DISRUPTORS AND THE DEVELOPING BRAIN: UNRAVELING HOW IMMUNOTOXICANTS SHAPE NEURODEVELOPMENT; DR. LENA SMIRNOVA RESEARCH GRANT- ADVANCING ORGANOID INTELLIGENCE WITH A HIPPOCAMPAL-CORTICAL SYSTEM MICHIGAN STATE UNIVERSITY 426 AUDITORIUM RD EAST LANSING MI 48824 386005984 501(C)(3) 50000 0 DR. AITOR AGUIRRE RESEARCH GRANT ENGINEERED HUMAN HEART MODELS FOR ADVANCING DRUG CARDIAC SAFETY ASSESSMENT PEOPLE FOR THE ETHICAL TREATMENT OF ANIMALS 501 FRONT ST NORFOLK VA 23510 521218336 501(C)(3) 5200 0 SUPPORT OF JOINTLY OPERATED ANTIBODY ALTERNATIVES PROGRAM UNIVERSITY OF ARIZONA ARIZONA BOARD OF REGENTS PO BOX 210158B TUCSON AZ 85721 742652689 501(C)(3) 49999 0 DR. JIAN GU RESEARCH GRANT IN VITRO MODELLING OF BUBBLE-ASSISTED FOCUSED ULTRASOUND BLOOD-BRAIN BARRIER OPENING UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NC 27599 566001393 501(C)(3) 49999 0 DR. JAMES HAGOOD RESEARCH GRANT AN ADVANCED EX VIVO MODEL FOR IDIOPATHIC PULMONARY FIBROSIS PART I, LINE 2: PROGRESS REPORTS FOR RESEARCH GRANTS ARE REQUIRED AFTER 8 MONTHS AND A FINAL REPORT IS DUE WHEN THE SUPPORTED PROGRAM IS COMPLETE. ANY UNUSED FUNDS MUST BE RETURNED OR USED FOR APPROVED PURPOSES ONLY. FORM 990, PART V, LINE 24 AND PART IX SALARIES REFLECTED ON THE STATEMENT OF FUNCTIONAL EXPENSES INCLUDE ALLOCATIONS OF SALARIES AS A PORTION OF MANAGEMENT EXPENSES THAT THE ORGANIZATION PAYS TO ITS AFFILIATE, THE AMERICAN ANTI-VIVISECTION SOCIETY. NOTE THAT TWO EMPLOYEES, SUE LEARY AND LUKE KLEIN, ARE PAID BY A COMMON PAYMASTER. THE ORGANIZATION'S AFFILIATE AMERICAN ANTI-VIVISECTION SOCIETY. THERE IS NO W-3 REPORTED FOR THIS ENTITY; ALL FILING REQUIREMENTS ARE MET THROUGH THE AFFILIATE AS MENTIONED. FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT, TREASURER AND BOARD OF DIRECTORS REVIEW THE FORM 990 BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION FOLLOWS THE POLICIES OF ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS), WITH WHICH IT SHARES ITS BOARD OF DIRECTORS. THE BOARD OF DIRECTORS MONITORS AND ENFORCES COMPLIANCE WITH THE CONFLICT OF INTEREST POLICIES (AS DETERMINED BY AAVS). ANNUAL DISCLOSURE FORMS ARE COLLECTED FROM EACH BOARD MEMBER AND REVIEWED BY THE PRESIDENT WHO ENSURES THAT MEMBERS RECUSE THEMSELVES FROM VOTING ON ANY MATTERS IN WHICH THEY MAY HAVE A DUAL INTEREST. THE BOARD OF DIRECTORS, EXCLUDING THE PRESIDENT, ENSURES THAT THE PRESIDENT RECUSES HERSELF/HIMSELF IN CASE OF A POTENTIAL CONFLICT OF INTEREST. THE CONFLICT OF INTEREST POLICY EXPLICITLY DEEMS FAMILY AND BUSINESS RELATIONSHIPS TO HAVE POTENTIAL FOR CONFLICTS AND REQUESTS DETAILED INFORMATION ON ANY SUCH RELATIONSHIPS AS PART OF THE ANNUAL CONFLICT OF INTEREST POLICY PROCESS. FORM 990, PART VI, SECTION B, LINE 15A THE ORGANIZATION'S COMPENSATION POLICIES ARE DICTATED BY ITS AFFILIATE, AMERICAN ANTI-VIVISECTION SOCIETY (AAVS) WITH WHOM IT SHARES A BOARD OF DIRECTORS. THE BOARD OF DIRECTORS DETERMINES COMPENSATION OF THE PRESIDENT BY COMPARING WITH COMPENSATION OF EQUIVALENT POSITIONS USING PUBLICLY AVAILABLE DATA. NOTE THE PRESIDENT'S SALARY IS DETERMINED BY AAVS BUT IS REPORTED ON BOTH RETURNS. DECISIONS ARE RECORDED IN BOARD MINUTES AND MATERIALS. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, THE CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G CONTRACT LABOR: PROGRAM SERVICE EXPENSES 215,071. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 215,071. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 124. MANAGEMENT AND GENERAL EXPENSES 393. FUNDRAISING EXPENSES 53. TOTAL EXPENSES 570. FORM 990, PART XI, LINE 9: UNREALIZED LOSS ON BENEFICIAL INTEREST IN PERPETUAL TRUST 36,854. FORM 990, PART XII, LINE 2C: THERE WAS NO CHANGE IN THE AUDIT OVERSIGHT PROCESS FROM THE PRIOR YEAR. AMERICAN ANTI-VIVISECTION SOCIETY 801 OLD YORK ROAD NOBLE PLAZA SUITE JENKINTOWN PA 19046 230341990 EDUCATE THE PUBLIC ON PROBLEMS OF ANIMAL EXPERIMENTATION PA 501(C)(3) LINE 7 NONE 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 AMERICAN ANTI-VIVISECTION SOCIETY L 93 FMV AMERICAN ANTI-VIVISECTION SOCIETY N 2631 FMV AMERICAN ANTI-VIVISECTION SOCIETY O 60844 FMV AMERICAN ANTI-VIVISECTION SOCIETY Q 191937 FMV